| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | U12 |
| Uniprot No | P52380 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-347aa |
| 氨基酸序列 | MDTVIELSKLQFKGNASCTSTPTLKTARIMESAVTGITLTTSIPMIIIVVTTMILYHRVAKHNATSFYVITLFASDFVLMWCVFFMTVNRKQLFSFNRFFCQLVYFIYHAVCSYSISMLAIIATIRYKTLHRRKKTESKTSSTGRNIGILLLASSMCAIPTALFVKTNGMKKTGKCVVYISSKKAYELFLAVKIVFSFIWGVLPTMVFSFFYVIFCKALHDVTEKKYKKTLFFIRILLLSFLLIQIPYIAILICEIAFLYMPQNTCFWLARVEILQLIIRLMPQVHCFSNPLVYAFTGGELRNRFTACFQSFFPKTLCSTQKRKDSDASEHDQNSKSKASVEKNQPL |
| 预测分子量 | 42.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于U12重组蛋白的3篇参考文献示例(注：文献信息为模拟生成，供参考)：
---
1. **标题**：*Structural Insights into the U12 Minor Spliceosome Component via Recombinant Protein Expression*
**作者**：Smith A, et al.
**摘要**：本研究通过重组表达技术纯化了U12 snRNP核心蛋白，并利用冷冻电镜解析其三维结构，揭示了U12在识别罕见内含子剪接位点中的关键构象变化，为次要剪接体功能机制提供新见解。
---
2. **标题**：*Functional Characterization of Recombinant U12 Proteins in Zebrafish Development*
**作者**：Chen L, et al.
**摘要**：通过构建重组U12蛋白突变体并在斑马鱼模型中验证，发现U12蛋白功能缺陷会导致胚胎神经发育异常，证明次要剪接体在脊椎动物早期发育中的必要性。
---
3. **标题**：*U12 Recombinant Protein Interaction Network Reveals Links to Neurodegenerative Diseases*
**作者**：Johnson R, et al.
**摘要**：利用重组U12蛋白进行蛋白质互作组学分析，发现其与RNA解旋酶DHX8等因子的相互作用，并提示U12剪接异常可能与脊髓小脑共济失调等神经退行性疾病相关。
---
**注**：以上文献为基于领域知识的模拟示例，实际研究中建议通过PubMed或Google Scholar以关键词“U12 recombinant protein”、“minor spliceosome”等检索最新论文。
**Background of U12 Recombinant Protein**
The U12 recombinant protein is closely associated with the minor spliceosome, a molecular machinery responsible for splicing a small subset of introns (<0.5% in humans) known as U12-type introns. Discovered in the 1980s, the minor spliceosome operates parallel to the major spliceosome but recognizes distinct splice site sequences, enabling precise removal of U12-type introns from pre-mRNA. The U12 small nuclear ribonucleoprotein (snRNP), a core component of this system, contains the U12 small nuclear RNA (snRNA) and specific proteins, including the U11/U12-65K protein, which is critical for spliceosome assembly and catalytic activity.
Recombinant U12-related proteins, such as U11/U12-65K, are engineered using expression systems (e.g., *E. coli* or mammalian cells) to study their structural and functional roles. These proteins help elucidate the minor spliceosome’s mechanisms, including its evolutionary conservation and tissue-specific regulation. Dysregulation of U12-dependent splicing is linked to developmental disorders and cancers, highlighting its biomedical relevance. For example, mutations in U12 spliceosome components are implicated in cerebellar ataxia and motor neuron diseases.
Recent advancements in cryo-EM and biochemical assays using recombinant U12 proteins have resolved high-resolution structures of minor spliceosome intermediates, revealing differences in assembly dynamics compared to the major spliceosome. Additionally, U12 recombinant tools aid in developing antisense oligonucleotides to modulate splicing in disease contexts.
Overall, U12 recombinant proteins serve as vital resources for decoding the biology of minor intron splicing, bridging gaps in understanding gene expression regulation, and exploring therapeutic strategies for spliceosome-related pathologies.
×
